Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, the Company has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and six active pre-clinical programs. The Company seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
TypePublic
HQNewtown, US
Founded1998
Size (employees)23 (est)
Websiteonconova.com
Onconova Therapeutics was founded in 1998 and is headquartered in Newtown, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Onconova Therapeutics

Ramesh Kumar

Ramesh Kumar

President and CEO

Onconova Therapeutics Office Locations

Onconova Therapeutics has an office in Newtown
Newtown, US (HQ)
375 Pheasant Run
Show all (1)
Report incorrect company information

Onconova Therapeutics Financials and Metrics

Onconova Therapeutics Revenue

Onconova Therapeutics's revenue was reported to be $787 k in FY, 2017
USD

Revenue (Q2, 2018)

1.0m

Net income (Q2, 2018)

(9.4m)

EBIT (Q2, 2018)

(11.5m)

Market capitalization (18-Oct-2018)

33.2m

Closing stock price (18-Oct-2018)

5.9

Cash (30-Jun-2018)

29.5m
Onconova Therapeutics's current market capitalization is $33.2 m.
Annual
USDFY, 2016FY, 2017

Revenue

5.5m787.0k

General and administrative expense

9.2m7.4m

R&D expense

20.1m19.1m

Operating expense total

29.2m26.5m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

125.0k114.0k114.0k123.0k1.6m1.5m2.2m1.7m210.0k110.0k564.0k1.0m

General and administrative expense

4.0m3.1m3.0m2.6m2.2m3.2m2.1m2.0m2.1m1.9m3.9m

R&D expense

12.9m11.9m9.5m6.5m5.3m5.8m5.6m4.0m4.9m4.6m8.6m

Operating expense total

16.9m15.0m12.5m9.1m7.5m9.0m7.6m6.0m7.0m6.9m6.5m12.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

60.0m43.6m19.8m21.4m4.0m

Accounts Receivable

141.8m59.0k

Inventories

4.4m3.2m1.8m

Current Assets

104.4m46.9m23.2m23.1m4.9m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

55.5m42.3m33.7m25.4m22.2m16.8m12.8m25.8m15.4m7.6m7.3m29.5m

Accounts Receivable

477.0k72.0k

Inventories

1.0m

Current Assets

73.8m61.6m36.4m27.4m25.7m19.4m16.0m27.9m16.4m8.7m8.6m30.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(62.6m)(63.8m)(24.0m)(19.7m)(24.1m)

Depreciation and Amortization

446.0k434.0k150.0k96.0k88.0k

Inventories

(2.7m)1.2m1.2m

Accounts Payable

(1.8m)317.0k(606.0k)1.9m863.0k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(16.8m)(14.9m)(12.4m)(9.0m)(5.9m)(7.2m)(5.4m)(1.6m)(8.3m)(7.0m)(5.1m)(9.4m)

Depreciation and Amortization

24.0k16.0k30.0k

Inventories

1.0m

Accounts Payable

5.0m5.4m3.9m4.2m3.2m(125.0k)2.8m4.1m5.4m5.4m848.0k456.0k
USDY, 2018

Financial Leverage

1.9 x
Show all financial metrics
Report incorrect company information

Onconova Therapeutics News and Updates

Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2018 Financial Results

Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Tuesday August 14, 2018 Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Tuesday August 14, 2018
Report incorrect company information

Onconova Therapeutics Blogs

Onconova Therapeutics Announces Issuance of a New U.S. Patent for Rigosertib

Granted claims cover both oral and injectable formulations of Rigosertib Newly issued US patent 10,098,862  extends protection for Rigosertib into 2037 Equivalent coverage is being sought worldwide and, if granted, will expand intellectual property protection for Rigosertib in additional countries

Onconova Therapeutics to Present Update at the 2018 BIO Investor Forum in San Francisco

NEWTOWN, Pa., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that the Company will

Onconova Therapeutics Announces Reverse Stock Split

Reverse split intended primarily to increase the per share bid price of Onconova's common stock and satisfy the Nasdaq Capital Market continued listing requirement NEWTOWN, Pa. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a Phase 3

Onconova Therapeutics Company Life and Culture

Report incorrect company information